BIOFRONTERA INC. PRE-FUNDED COMMON STOCK PURCHASE WARRANTBiofrontera Inc. • October 27th, 2023 • Pharmaceutical preparations • New York
Company FiledOctober 27th, 2023 Industry JurisdictionTHIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on October [●], 2028 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Biofrontera Inc., a Delaware corporation (the “Company”), up to [ ] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • October 27th, 2023 • Biofrontera Inc. • Pharmaceutical preparations • New York
Contract Type FiledOctober 27th, 2023 Company Industry Jurisdiction
WARRANT AGENT AGREEMENTWarrant Agent Agreement • October 27th, 2023 • Biofrontera Inc. • Pharmaceutical preparations • New York
Contract Type FiledOctober 27th, 2023 Company Industry JurisdictionThis Warrant Agent Agreement (“Warrant Agreement”) is made as of October [__], 2023, by and among Biofrontera Inc., a Delaware corporation, with offices at 120 Presidential Way, Suite 330, Woburn, Massachusetts 01801 (the “Company”), and Computershare Inc., a Delaware corporation (“Computershare”), and its affiliate Computershare Trust Company, N.A. a federally chartered trust company (collectively with Computershare, the “Warrant Agent”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 27th, 2023 • Biofrontera Inc. • Pharmaceutical preparations • New York
Contract Type FiledOctober 27th, 2023 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is dated as of October [__], 2023, between Biofrontera Inc., a Delaware corporation (the “Company”), and the purchasers identified on the signature pages hereto (including each purchaser’s successors and assigns, individually, a “Purchaser”, in the aggregate, the “Purchasers”).